Valuation: FibroBiologics, Inc.

Market Cap 4.15M 3.66M 3.37M 3.16M 5.91M 392M 6.02M 40.54M 15.7M 193M 15.6M 15.26M 672M P/E 2026 *
-0.78x
P/E 2027 * -0.35x
Enterprise Value 4.15M 3.66M 3.37M 3.16M 5.91M 392M 6.02M 40.54M 15.7M 193M 15.6M 15.26M 672M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day+2.55%
1 week-3.82%
Current month-33.67%
1 month-26.72%
3 months-85.05%
6 months-83.69%
Current year-82.89%
1 week 0.74
Extreme 0.745
0.84
1 month 0.74
Extreme 0.745
1.17
Current year 0.74
Extreme 0.745
9.6
1 year 0.74
Extreme 0.745
15
3 years 0.74
Extreme 0.745
1,100
5 years 0.74
Extreme 0.745
1,100
10 years 0.74
Extreme 0.745
1,100
Manager TitleAgeSince
Chief Executive Officer 62 08/04/2021
Director of Finance/CFO 53 09/06/2025
Chief Tech/Sci/R&D Officer 57 01/08/2021
Director TitleAgeSince
Director/Board Member 60 08/04/2021
Chairman 62 08/04/2021
Director/Board Member 51 08/04/2021
Date Insider Type Main position Quantity % Market Cap.
06-23Free

Director

30,803 0.5914%
06-23Free

Director

30,803 0.5914%
06-23Free

Director

30,803 0.5914%
Change 5-day change 1-year change 3-year change Capi.($)
+2.55%-3.82%-94.84% - 4.15M
+0.53%-1.36%+55.74%+110.17% 52.88B
+8.55%+17.52%+72.65%+82.31% 50.98B
-0.45%-2.18%-14.16%-15.80% 22.81B
+1.28%+5.09%-2.30%+418.34% 22.43B
+2.03%+7.40%+28.79%-13.91% 17.01B
-0.47%+4.30%+29.00%-34.71% 15.91B
+2.98%+0.82%+15.64%+166.21% 13.29B
+5.94%+14.85%+134.05%+296.09% 13.58B
-0.71%+1.98%+78.88%+114.48% 11.75B
Average +2.22%+4.30%+30.35%+124.80% 22.06B
Weighted average by Cap. +2.81%+5.40%+46.15%+117.06%

Financials

2026 *2027 *
Net sales - -
Net income -20.36M -17.92M -16.53M -15.46M -28.97M -1.92B -29.51M -199M -76.95M -947M -76.43M -74.77M -3.29B -24.01M -21.14M -19.5M -18.24M -34.17M -2.26B -34.81M -234M -90.77M -1.12B -90.15M -88.2M -3.88B
Net Debt - -
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Employees
15
Date Price Change Volume
24/06/26 $0.7694 +2.55% 151,731
23/06/26 $0.7503 -6.85% 247,256
22/06/26 $0.8055 +4.58% 158,132
18/06/26 $0.7702 -3.73% 160,437
17/06/26 $0.8000 -1.23% 135,830
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7694USD
Average target price
13.50USD
Spread / Average Target
+1,654.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBLG Stock